Luis Hernandez
Overview
Explore the profile of Luis Hernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
2413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Casas Deza D, Alcedo J, Lafuente M, Lopez F, Perez-Aisa A, Pavoni M, et al.
Am J Gastroenterol
. 2025 Feb;
PMID: 39902822
Introduction: To evaluate the prescription patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe. Methods: International, prospective, noninterventional registry of the clinical practice of the...
2.
Melgar M, Sajmolo I, Choco A, Ortiz L, Cordova A, Hernandez L, et al.
PLOS Glob Public Health
. 2025 Jan;
5(1):e0004165.
PMID: 39854564
Varicella presents a public health challenge in Guatemala, with limited evidence regarding its impact; vaccine is currently absent from the national immunization program. Generating local data on the economic and...
3.
Olmedo L, Calvet X, Gene E, Bordin D, Voynovan I, Castro-Fernandez M, et al.
Gut
. 2024 Oct;
74(1):15-25.
PMID: 39461739
Background: Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating infection even in areas of high...
4.
Chaparro M, Hermida S, Acosta D, Fernandez-Clotet A, Barreiro-de Acosta M, Hernandez Martinez A, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(10):1325-1338.
PMID: 39287363
Background: Ustekinumab is approved for ulcerative colitis (UC). Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice. Methods:...
5.
Walji H, Martin E, Brookes T, Ellis S, Kolokotroni M, Hernandez L, et al.
J Thorac Dis
. 2024 Sep;
16(8):5042-5049.
PMID: 39268096
Background: Lung cancer is the most common cause of cancer death in the UK resulting in 21% of all cancer deaths. In 2016, local lung cancer surgery services required improvement...
6.
Singh S, Gleason C, Fang M, Laimon Y, Khivansara V, Xie S, et al.
bioRxiv
. 2024 Aug;
PMID: 39211113
Cancer cell proliferation requires precise control of E2F1 activity; excess activity promotes apoptosis. Here, we developed cell-permeable and bioavailable macrocycles that selectively kill small cell lung cancer (SCLC) cells with...
7.
Paly V, Li S, Khanduri P, Asfaw A, Zou D, Hernandez L
J Med Econ
. 2024 Aug;
27(1):1076-1085.
PMID: 39102473
Aims: Fruquintinib is a selective small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 recently approved in the United States (US) for the treatment...
8.
Lim E, Harris R, Batchelor T, Casali G, Krishnadas R, Begum S, et al.
JTCVS Open
. 2024 Jul;
19:296-308.
PMID: 39015471
Objectives: Surgery through a single port may be less painful because access is supplied by 1 intercostal nerve or more painful because multiple instruments are used in 1 port. We...
9.
Martinez-Dominguez S, Nyssen O, Lanas A, Alfaro E, Jonaitis L, Mahmudov U, et al.
Helicobacter
. 2024 Jul;
29(4):e13111.
PMID: 39001621
Background: The influence of indications for Helicobacter pylori investigation on prescriptions and effectiveness is unknown. The aim of the study was to assess the impact of indications for H. pylori...
10.
Paly V, Dasari A, Hubbard J, Bekaii-Saab T, Padukkavidana T, Hernandez L
J Comp Eff Res
. 2024 Jul;
13(8):e240084.
PMID: 38976346
The objective of this study was to compare adverse event (AE) management costs for fruquintinib, regorafenib, trifluridine/tipiracil (T/T) and trifluridine/tipiracil+bevacizumab (T/T+bev) for patients with metastatic colorectal cancer (mCRC) previously treated...